1.
接受治疗的患者基线临床特征的比较
Baseline Patient and Disease Characteristics for Patients received study treatment
| Variable | Pemetrexed/Cisplatin (n=144) | Gemcitabine/Cisplatin (n=144) | P |
| *Partial clinical data of a patient in GC group were missed. PS: performance status. | |||
| Age (yr) | 0.99 | ||
| Median (Range) | 55 (27-77) | 56 (27-73) | |
| Gender | 0.24 | ||
| Male | 84 (58.3%) | 73 (50.7%) | |
| Female | 60 (41.7%) | 71 (49.3%) | |
| PS status* | 0.13 | ||
| 0 | 25 (17.4%) | 34 (23.8%) | |
| 1 | 111 (77.1%) | 104 (72.7%) | |
| 2 | 8 (5.5%) | 5 (3.5%) | |
| Histology* | 0.50 | ||
| Adenocarcinoma | 140 (97.2%) | 142 (99.3%) | |
| Large cell | 3 (2.1%) | 1 (0.7%) | |
| Mixed | 1 (0.7%) | 0 | |
| Staging* | 0.19 | ||
| Ⅲb | 26 (18.1%) | 17 (11.9%) | |
| Ⅳ | 118 (81.9%) | 126 (88.1%) | |
| Adjuvant chemo history* | 0.77 | ||
| No | 139 (96.5%) | 137 (95.8%) | |
| Yes | 5 (3.5%) | 6 (4.2%) | |
| Radiotherapy history | 0.99 | ||
| No | 136 (94.4%) | 137 (95.1%) | |
| Yes | 8 (5.6%) | 7 (4.9%) | |
| Surgical history | 0.40 | ||
| No | 108 (75.0%) | 115 (79.9%) | |
| Yes | 36 (25.0%) | 29 (20.1%) | |
| Concurrent disease | 0.23 | ||
| No | 89 (61.8%) | 78 (54.2%) | |
| Yes | 55 (38.2%) | 66 (45.8%) | |